H.C. Wainwright raises Annexon stock price target on GBS approval prospects
H.C. Wainwright raised its price target for Annexon Biosciences (ANNX) to $25, citing catalysts like the tanruprubart BLA submission for GBS and ARCHER II readout for vonaprument. The firm values these at $11.70 and $13.60 per share, respectively. ANNX trades at $3.96, down 38% in six months, with a strong balance sheet but high cash burn. Recent Q2 loss was $0.28 per share. Other analysts also raised targets and ratings.
How this was made
The 30-second read
Why it matters
Analyst upgrades and a new $25 price target reflect optimism around upcoming Phase 3 data, potentially driving short‑term buying interest.
Market read
The combined analyst upgrades could spark a modest rally in ANNX, with broader biotech sentiment potentially benefiting peers.
What to watch
Cash burn of $193 M annually may constrain runway if trial results are delayed.
Background
Annexon Biosciences is a small-cap biotech developing therapies for Guillain‑Barré syndrome and geographic atrophy.
Ticker impact
H.C. Wainwright raised its price target on Annexon Biosciences to $25 and noted upcoming trial readouts as catalysts.
likely upward pressure as investors price in the higher target and trial expectations
Target increase from $14 to $25 reflects strong belief in trial success; similar upgrades from Citizens and JPMorgan reinforce the bullish view.
Market effects
Positive sentiment may lift other biotech stocks focused on neurology and ophthalmology.
Limited to US-listed biotech sector.
Minimal global impact beyond niche biotech investors.
Counterpoint
The trial readouts remain uncertain; a miss could quickly reverse the price target hike.
Key entities
- analystH.C. Wainwright
Raised price target to $25, maintains Buy rating.
- analystCitizens
Upgraded rating to Market Perform.
- analystJPMorgan
Raised price target to $15, maintains Overweight.
